A Metabolic Study of Huntington’s Disease
Open Access
- 8 January 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (1) , e0146480
Abstract
Huntington’s disease patients have a number of peripheral manifestations suggestive of metabolic and endocrine abnormalities. We, therefore, investigated a number of metabolic factors in a 24-hour study of Huntington’s disease gene carriers (premanifest and moderate stage II/III) and controls. Control (n = 15), premanifest (n = 14) and stage II/III (n = 13) participants were studied with blood sampling over a 24-hour period. A battery of clinical tests including neurological rating and function scales were performed. Visceral and subcutaneous adipose distribution was measured using magnetic resonance imaging. We quantified fasting baseline concentrations of glucose, insulin, cholesterol, triglycerides, lipoprotein (a), fatty acids, amino acids, lactate and osteokines. Leptin and ghrelin were quantified in fasting samples and after a standardised meal. We assessed glucose, insulin, growth hormone and cortisol concentrations during a prolonged oral glucose tolerance test. We found no highly significant differences in carbohydrate, protein or lipid metabolism markers between healthy controls, premanifest and stage II/III Huntington’s disease subjects. For some markers (osteoprotegerin, tyrosine, lysine, phenylalanine and arginine) there is a suggestion (p values between 0.02 and 0.05) that levels are higher in patients with premanifest HD, but not moderate HD. However, given the large number of statistical tests performed interpretation of these findings must be cautious. Contrary to previous studies that showed altered levels of metabolic markers in patients with Huntington’s disease, our study did not demonstrate convincing evidence of abnormalities in any of the markers examined. Our analyses were restricted to Huntington’s disease patients not taking neuroleptics, anti-depressants or other medication affecting metabolic pathways. Even with the modest sample sizes studied, the lack of highly significant results, despite many being tested, suggests that the majority of these markers do not differ markedly by disease status.Keywords
This publication has 72 references indexed in Scilit:
- Body composition in premanifest Huntington’s disease reveals lower bone density compared to controls.PLoS Currents, 2011
- Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's diseaseEuropean Journal of Human Genetics, 2010
- Altered cholesterol and fatty acid metabolism in Huntington diseaseJournal of Clinical Lipidology, 2010
- Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse modelsHuman Molecular Genetics, 2009
- Central Nervous System Regulation of Energy MetabolismAnnals of the New York Academy of Sciences, 2008
- Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease ProgressionPLOS ONE, 2007
- Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic ImplicationsReviews in the Neurosciences, 2007
- Hypothalamic–endocrine aspects in Huntington's diseaseEuropean Journal of Neuroscience, 2006
- Validity of a new automated software program for visceral adipose tissue estimationInternational Journal of Obesity, 2006
- Unified Huntington's disease rating scale: A follow upMovement Disorders, 1998